The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Boceprevir Officially Fast-Tracked

Back to News Homepage

Next

Two Supplements May Strengthen Hep C Antiviral Treatment

Early Hepatitis C Trial Data Shows INX-189 to Be Effective

January 14, 2011

Print this page

Interim data from a Phase 1b trial of Inhibitex’s INX-189 demonstrates potent antiviral activity against the Hepatitis C virus.

Inhibitex Reports Positive Data From Ongoing Phase 1b Clinical Trial Of INX-189

1/9/2011

(RTTNews) – Inhibitex, Inc. (INHX: News ) reported positive preliminary interim safety and antiviral data from the first two monotherapy cohorts of its ongoing Phase 1b clinical trial of INX-189, an oral NS5b nucleotide inhibitor being developed to treat chronic infections caused by hepatitis C virus or HCV.

The company added that the trial, which is being conducted under an IND in the United States, is a double-blind, placebo-controlled, dose escalation study, administered orally once-daily for seven days, for the treatment of HCV genotype 1 treatment naïve patients. Each treatment cohort in the study is comprised of 10 patients, eight that receive INX-189 and two that receive placebo.

Continue reading this entire article:
http://www.rttnews.com/Content/QuickFacts.aspx?Id=1522611&SM=1

No Comments - be the first!
Share
Share

Previous

Boceprevir Officially Fast-Tracked

Back to News Homepage

Next

Two Supplements May Strengthen Hep C Antiviral Treatment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.